Circulation: The effect of colchicine on acute myocardial injury

Inflammation is a key factor for myocardial injury in patients with ST-segment elevation myocardial infarction
.

Recently, the heart blood vessels published on the prestigious journal Circulation areas of the research article, the researchers assumed that colchicine is a potent anti-inflammatory agent, can reduce infarct size in patients with acute ST-segment elevation myocardial infarction (IS) and left The degree of ventricular (LV) remodeling
.

In this double-blind multicenter trial, the researchers randomly assigned the first ST-segment elevation myocardial infarction hospitalized patients undergoing percutaneous coronary intervention to receive oral colchicine (2 mg loading dose, followed by 2 per day) from admission to day 5.
0.
5mg each time) or matching placebo treatment
.
The main efficacy outcome of the study was IS determined by cardiac magnetic resonance imaging on day 5

The study recruited 192 patients, including 101 in the colchicine group and 91 in the control group
.
At 5 days, there was no difference in IS defined by gadolinium enhancement between the colchicine group and the placebo group.

It can be seen that in this randomized, placebo-controlled trial, oral high-dose colchicine during reperfusion and 5 days did not reduce IS assessed by cardiac magnetic resonance imaging
.

Original source:

Nathan Mewton,et al.